INSM
Insmed Incorporated Common Stock
$125.80
장중 · Vol 96.6K · 52주 $90.39–$212.75 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $119.57 · Aug 31, 2026
INSM 가격 추세
종가
$119.57
시가
$119.00
고가
$119.71
저가
$117.63
30초 브리핑
INSM 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 29%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 151.8배
업종 피어 비교 전에는 고평가·저평가를 단정하기 어렵습니다.
20일 평균의 0.5배
거래 참여가 낮아 현재 움직임의 신뢰도가 제한적입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
INSM 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
700 US Highway 202/206 · Bridgewater, NJ, United States · 직원 1,664명
시가총액
$26.60B
Trailing P/E
—
최근 12개월 이익 기준
Forward P/E
151.8
EPS (TTM)
$-4.24
배당 수익률
—
배당성향
0.0%
베타
0.79
시장보다 방어적
ROE
-87.2%
P/B
35.11
EV/EBITDA
-32.0
52주 범위
$90.39 – $212.75
현재 위치 29%
거래량
1.12M
20일 평균 2.34M · 0.5배
애널리스트 의견
매수 100%
총 23명 · 0m
DITM LEAPS Analysis
INSM 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INSM280121C00065000 | 1/21/28 · 1.4Y | $65.00 | $66.00 | 1.6x | 0.8937 | 13.9% | 7.58% | 70.58% | 203 | 77.39 | |
| INSM280121C00070000 | 1/21/28 · 1.4Y | $70.00 | $60.00 | 1.8x | 0.8879 | 13.6% | 8.33% | 61.21% | 62 | 77.12 | |
| INSM280121C00080000 | 1/21/28 · 1.4Y | $80.00 | $53.50 | 1.9x | 0.8495 | 21.8% | 7.48% | 60.45% | 58 | 69.55 | |
| INSM280121C00075000 | 1/21/28 · 1.4Y | $75.00 | $59.00 | 1.8x | 0.8611 | 20.6% | 8.47% | 67.65% | 5 | 67.23 | |
| INSM280121C00085000 | 1/21/28 · 1.4Y | $85.00 | $50.25 | 2.0x | 0.8297 | 26.7% | 8.96% | 59.51% | 44 | 64.69 | |
| INSM280121C00090000 | 1/21/28 · 1.4Y | $90.00 | $47.25 | 2.1x | 0.8087 | 32.7% | 9.52% | 58.89% | 133 | 60.85 | |
| INSM271119C00090000 | 11/19/27 · 1.2Y | $90.00 | $46.00 | 2.1x | 0.8084 | 30.8% | 8.70% | 59.75% | 10 | 58.98 | |
| INSM280121C00095000 | 1/21/28 · 1.4Y | $95.00 | $44.50 | 2.1x | 0.7870 | 39.7% | 8.99% | 58.55% | 189 | 55.96 | |
| INSM280121C00100000 | 1/21/28 · 1.4Y | $100.00 | $41.75 | 2.2x | 0.7649 | 47.7% | 10.78% | 57.92% | 278 | 50.05 | |
| INSM280121C00097500 | 1/21/28 · 1.4Y | $97.50 | $45.25 | 2.1x | 0.7750 | 46.3% | 9.94% | 62.90% | 29 | 48.66 | |
| INSM271119C00100000 | 11/19/27 · 1.2Y | $100.00 | $40.50 | 2.3x | 0.7620 | 46.1% | 9.88% | 59.05% | 41 | 48.43 |
재무제표
INSM 연간 손익·현금흐름·재무상태
매출 성장률
+66.7%
최근 연간 YoY
EPS 성장률
-15.3%
최근 연간 YoY
영업이익률
-164.0%
최근 연간
FCF 마진
-159.6%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $606.42M+66.7% | $363.71M+19.2% | $305.21M+24.4% | $245.36M |
| 매출총이익 | $483.49M+73.9% | $277.96M+16.0% | $239.63M+26.0% | $190.23M |
| 영업이익 | -$994.78M-26.5% | -$786.57M-15.5% | -$680.93M-42.4% | -$478.12M |
| 순이익 | -$1.28B-39.7% | -$913.77M-21.9% | -$749.57M-55.7% | -$481.53M |
| 희석 EPS | $-6.42-15.3% | $-5.57-4.3% | $-5.34-36.6% | $-3.91 |
| EBITDA | -$1.18B-43.8% | -$818.79M-24.0% | -$660.18M-47.6% | -$447.37M |
| 영업현금흐름 | -$935.01M-36.7% | -$683.88M-27.5% | -$536.25M-33.9% | -$400.44M |
| 잉여현금흐름 | -$967.58M-37.1% | -$705.80M-28.4% | -$549.53M-33.9% | -$410.32M |
| 총자산 | $2.26B+11.8% | $2.03B+52.3% | $1.33B-19.7% | $1.66B |
| 총부채 | — | — | — | — |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
INSM 실적·배당 일정
매출 하단
$457.00M
EPS 하단
$-0.90
매출 상단
$524.08M
실적 발표일
2026-10-29
D-58
EPS 상단
$0.04
매출 컨센서스
$501.20M
EPS 컨센서스
$-0.36
뉴스
INSM 관련 최신 기사
제품·기술Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks · Aug 31, 2026
일반Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Zacks · Aug 27, 2026
실적Insmed (INSM) Q2 2026 Earnings Call Transcript
BRINSUPRI revenue surged to $309.2 million, driving total revenues to $425.5 million.
Motley Fool · Aug 13, 2026
- 제품·기술
What Insmed Stock's Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
Trefis · Aug 7, 2026
- 제품·기술
Has Insmed (INSM) Risen Above Fair Value After Its 3 Year Run?
Insmed stock has delivered a very large 3 year return, yet the current valuation checks and market multiples point to a price that leans expensive rather than clearly cheap. Insmed has returned roughly 4.8x over the past 3 years, which puts the recent performance firmly in the spotlight for anyone thinking about new money going in at current levels. Expectations around the company’s rare disease therapy pipeline can support the current price, while execution risk in ongoing clinical...
Simply Wall St. · Aug 7, 2026
- 실적
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
Zacks · Aug 7, 2026
실적Insmed Incorporated Q2 2026 Earnings Call Summary
Moby summary of Insmed Incorporated's Q2 2026 earnings call
Moby · Aug 7, 2026
- 제품·기술
US Stock Market Today S&P 500 Futures Edge Higher On Mixed Growth Signals
The Morning Bull - US Market Morning Update Friday, Aug, 7 2026 US stock futures are slightly higher this morning, with E mini S&P 500 contracts up about 0.2%, as investors weigh strong services activity against softer hiring and shifting interest rate expectations. The composite PMI for July sits at 54.5, which is a broad scorecard showing private sector growth at a nine month high. However, input costs are at a 14 month high, so the cost of doing business is still rising. At the same time,...
Simply Wall St. · Aug 7, 2026
- 실적
Insmed (INSM) Is Up 30.6% After Steeply Narrowing Losses And Raising 2026 Revenue Guidance – What’s Changed
Insmed Incorporated reported second-quarter 2026 results showing its net loss shrinking to US$13.24 million from US$321.69 million a year earlier, alongside strong revenue growth from BRINSUPRI and ARIKAYCE. The company also raised its 2026 revenue guidance and increased combined peak sales estimates for its three lead programs to more than US$14 billion, highlighting how its lung therapies are reshaping its financial profile. We’ll now examine how this combination of sharply lower losses...
Simply Wall St. · Aug 7, 2026
- 실적
Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here’s What to Watch Next
Insmed (NASDAQ:INSM) saw its share price increase by 33.86 percent on Thursday to close at $132.55 apiece after nearly quadrupling its revenues in the second quarter of the year, thanks to a strong uptake from its treatment for non-cystic fibrosis bronchiectasis (NCFB). In an updated report, the company said that total revenues soared by 296 […]
Insider Monkey · Aug 7, 2026
홀더
INSM 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
104.9%
기관 보유 (유동주식)
105.5%
내부자 보유
0.5%
기관 수
973
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| FMR, LLC | 16.14M | $1.97B | 7.4% | 22.7% | Jun 30, 2026 |
| Blackrock Inc. | 15.81M | $1.93B | 7.2% | -5.2% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 10.43M | $1.27B | 4.8% | -56.8% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 10.41M | $1.27B | 4.8% | 0.3% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 9.79M | $1.19B | 4.5% | 1.5% | Jun 30, 2026 |
| Baker Bros. Advisors, LP | 8.80M | $1.07B | 4.0% | 18.5% | Jun 30, 2026 |
| Capital International Investors | 8.24M | $1.00B | 3.8% | 47.2% | Jun 30, 2026 |
| Darwin Global Management, Ltd. | 6.43M | $783.44M | 2.9% | -61.7% | Jun 30, 2026 |
| Ameriprise Financial, Inc. | 6.18M | $752.80M | 2.8% | 102.1% | Jun 30, 2026 |
| Orbis Allan Gray Ltd | 6.08M | $740.24M | 2.8% | 224.5% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.